Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $...

Buzz on the Bullboards: One Step Closer to a Canadian-Made COVID Vaccine?

(Image via Theralase Technologies Inc.) Clinical-stage pharmaceutical company Theralase Technologies Inc. ( TSX-V: TLT , Forum ) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. In collaboration with the University of Manitoba (UM), t...

Buzz on the Bullboards: Buying Binge or Sell-Off Frenzy?

Adrift in a sea of global economic uncertainty and confusion, last week was full of tough questions for investors on the Stockhouse Bullboards. Some of the most popular companies on the website suffered setbacks, while other small caps gained attention as investors looked...

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News

Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. Early this morning, clinical-stage biopharmaceutical company Alder BioPharmaceu...

Buzz on the Bullboards: Don’t Get Spooked by these Market Performers

There is nothing scarier on Hallowe’en than an uncertain stock market. Lately, this is exactly what investors have been dealing with and part of what we try to demystify at Stockhouse. There have been many companies moving independent of the market...